Abstract Search

ey0019.3-12 | Autoimmune Thyroid Disease | ESPEYB19

3.12. The 2022 European Thyroid Association guideline for the management of pediatric Graves' disease

CF Mooij , TD Cheetham , FA Verburg , A Eckstein , SH Pearce , J Leger , ASP van Trotsenburg

Eur Thyroid J. 2022 Jan 1;11(1):e210073. doi: 10.1530/ETJ-21-0073. PMID: 34981748The 2022 European Thyroid Association Guidelines for the management of Graves disease in the pediatric age group is an important document summarizing all aspects of the disease, ranging from diagnosis, medical treatment with its advantages and side effects, definitive treatment by thyroidectomy or radioiodine a...

0 shares

ey0016.6-2 | New Functions of (Old) Genes | ESPEYB16

6.2. Epigenetic repression of androgen receptor transcription in mutation-negative androgen insensitivity syndrome (AIS type II)

NC Hornig , P Rodens , H Dorr , NC Hubner , AE Kulle , HU Schweikert , M Welzel , S Bens , O Hiort , R Werner , S Gonzalves , AK Eckstein , M Cools , A Verrijn-Stuart , HG Stunnenberg , R Siebert , O Ammerpohl , PM Holterhus

J Clin Endocrinol Metab. 2018 Dec 1;103(12):46174627.doi: 10.1210/jc.2018-00052. PMID: 30124873This study shows for the first time that epigenetic changes in the androgen receptor gene (AR) proximal promoter region may underlie a clinical phenotype of Androgen Insensitivity Syndrome (AIS) in individuals in whom no DNA sequence mutation in AR or ...

0 shares

ey0017.3-5 | Follow-up paper - Graves disease | ESPEYB17

3.5. Teprotumumab for the treatment of active thyroid eye disease

RS Douglas , GJ Kahaly , A Patel , S Sile , EHZ Thompson , R Perdok , JC Fleming , BT Fowler , C Marcocci , M Marino , A Antonelli , R Dailey , GJ Harris , A Eckstein , J Schiffman , R Tang , C Nelson , M Salvi , S Wester , JW Sherman , T Vescio , RJ Holt , TJ Smith

To read the full abstract: N Engl J Med. 2020;382:341352.Teprotumumab, an IGF-1R monoclonal antibody, showed promising results for the treatment of Graves orbitopathy in a first phase 2 study reported in 2017 [1]. Here, this randomized double-masked, placebo controlled phase 3 multicenter study confirms those initial promising results in patients with moderate-to severe Graves eye disease: The primary outcome of proptosis reduc...

0 shares

ESPE Yearbook of Paediatric Endocrinology

3.12. The 2022 European Thyroid Association guideline for the management of pediatric Graves' disease

6.2. Epigenetic repression of androgen receptor transcription in mutation-negative androgen insensitivity syndrome (AIS type II)

3.5. Teprotumumab for the treatment of active thyroid eye disease

BiosciAbstracts